MME and heart failure: In the past decade, a new class of drugs, namely angiotensin receptor/neprilysin inhibitors (ARNi), was incorporated into the management of patients with heart failure with reduced ejection fraction (HFrEF), owing to the practice-changing results of the PARADIGM-HF trial [8].